ERBB2 and ovarian cancer: Trastuzumab labeled with the β-particle emitter, 177Lu was cytotoxic in vitro to HER2-positive human SK-BR-3 and MDA-MB-453 human BC cells and SK-OV-3 ovarian cancer cells (Sharma et al. 2020).